These results agree with a study performed by Tao et al. [49], where they found that the expression levels of FASN were higher in CNS WHO grade 3 and 4 gliomas (62-fold) than in CNS WHO grade 1 and 2 gliomas. Here, FASN is linked to central nervous system cancer.